Cytokinetics CYTK Cash ratio
Cash ratio at other companies
Other financials
Where this comes from
Calculated from Cytokinetics’s reported figures.
Based on the most recent quarter.
The official record: Cytokinetics’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →
Ask your AI about Cytokinetics's cash ratio.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Cytokinetics's cash ratio?
- Cytokinetics (CYTK) reported cash ratio of 0.7× in Q1 2026.
- How has Cytokinetics's cash ratio changed year-over-year?
- Cytokinetics's cash ratio increased by 41.3% year-over-year, from 0.5× to 0.7×.
- What is the long-term trend for Cytokinetics's cash ratio?
- Over 5 years (2020 to 2025), Cytokinetics's cash ratio has grown at a -25.6% compound annual growth rate (CAGR), from 2.7× to 0.6×.
- What does cash ratio mean?
- How much of its short-term bills the company could pay with cash on hand right now.
- How do you interpret cash ratio?
- A buffer against stress, but persistently high cash ratios can indicate under-deployed capital. Interpret alongside the company's capital-allocation strategy.
- How does cash ratio compare across companies?
- Varies widely by business model and treasury policy; best read against the company's own history.